Randomized clinical trials in ANCA-associated vasculitis: a systematic analysis of the WHO - International Clinical Trials Registry Platform
Open Access
- 29 May 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Orphanet Journal of Rare Diseases
- Vol. 15 (1), 1-8
- https://doi.org/10.1186/s13023-020-01408-6
Abstract
The analysis of the main features of randomized controlled trials (RCTs) on ANCA-associated vasculitis (AAV) can inform future study design. We searched within the International Clinical Trials Registry Platform all registered RCTs on AAV from October 2008 to December 2018. Two reviewers selected studies according to pre-specified eligibility criteria. We retrieved information including countries, funding, design, sample sizes, eligibility criteria, primary outcomes (POs), and treatments. Among the 40 RCTs identified, 22 (55%) were conducted in Europe, 29 (72,5%) in a single country, 14 (35%) were industry-funded. The median number of patients planned to enrol was 68 (IQR 36–138). Only 28% of RCTs targeted a single vasculitis, and ANCA negative patients were not included in about 40% of studies. Interventions investigated were mainly drugs given to induce (40%) or maintain (32.5%) remission. Eighty-five percent of POs were considered being ‘patient-important’, but discrepancies in definition of disease states, such as remission or relapse were observed. Glucocorticoids use was part of the PO in < 25% of studies. The number of trials targeting a single disease, non-industry funded, incorporating glucocorticoids in PO, as well as the planned sample size increased over time. Despite the important achievements in the field, a better harmonization of eligibility, and outcome criteria across studies is an important objective to pursue in next future.Keywords
Other Versions
This publication has 28 references indexed in Scilit:
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with PolyangiitisNew England Journal of Medicine, 2017
- Granulomatosis with polyangiitis according to geographic origin and ethnicity: clinical-biological presentation and outcome in a French populationRheumatology, 2016
- Issues in trial design for ANCA-associated and large-vessel vasculitisNature Reviews Rheumatology, 2014
- Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?Annals Of The Rheumatic Diseases, 2013
- Eosinophilic granulomatosis with polyangiitis (Churg‐Strauss): Clinical characteristics and long‐term followup of the 383 patients enrolled in the French Vasculitis Study Group cohortArthritis & Rheumatism, 2012
- Modification and validation of the Birmingham Vasculitis Activity Score (version 3)Annals Of The Rheumatic Diseases, 2008
- Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task forceAnnals Of The Rheumatic Diseases, 2007
- Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg‐Strauss syndromeArthritis & Rheumatism, 2005
- Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.1994
- Nomenclature of Systemic VasculitidesArthritis & Rheumatism, 1994